Dr Fendrick asked panelists what they think about the idea of centers of excellence for specific cancers and an evidence-based steerage.
Dr Fendrick asked panelists what they think about the idea of centers of excellence for specific cancers and an evidence-based steerage. “There may be a value in having a centralized guidance of treatments adapted to a particular patient,” said Dr Ribas. Dr Ribas also discussed the effect future agents being developed for the treatment of melanoma will have on the market. He says prices will be adapted to the benefit due to more competition in the marketplace.
“Perhaps there is some relief on the horizon in terms of pricing because of competition,” said Dr Weber. “Classic essence of capitalism.”
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More